

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM2/18 - Therapeutic Drugs

Dead line: 12.10.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}			
Set of samples 1																	
(81) Digoxin					125			0				125	124	99%			
Samples and groups		[nmol/L]															
Sample A1		1,58	0,22	14	125			0	CRV	1,583	0,016	36%	1,01	2,16	125	125	100%
(1) Abbott		1,34	0,10	7,5	36	0									36		
(12) Beckman Coulter		1,66	0,12	7,2	12	0									12		
(29) Siemens (DPC)		1,88	0,03	1,6	5	0									5		
(58) Beckman Coulter (Olympus)		1,68	0,16	9,7	12	0									12		
(60) Roche		1,60	0,12	7,7	35	0									35		
(179) Siemens (Bayer)		1,78	0,12	6,9	17	0									17		
Other					8	0									8		

Sample B1		2,71	0,31	12	125			0	CRV	2,688	0,027	36%	1,72	3,66	125	124	99%
(1) Abbott		2,39	0,16	6,6	36	0									36		
(12) Beckman Coulter		2,81	0,22	7,9	12	0									12		
(29) Siemens (DPC)		3,18	0,11	3,5	5	0									5		
(58) Beckman Coulter (Olympus)		2,84	0,16	5,6	12	0									12		
(60) Roche		2,74	0,19	7,0	35	0									35		
(179) Siemens (Bayer)		3,01	0,13	4,3	17	0									17		
Other					8	0									8		

(82) Theophylline					88			0				88	86	98%			
Samples and groups		[µmol/L]															
Sample A1		36,8	2,6	7,2	88			0	CRV	37,2	0,37	24%	28,2	46,2	88	87	99%
(1) Abbott		36,4	2,3	6,3	26	0									26		
(12) Beckman Coulter		36,3	0,44	1,2	5	0									5		
(29) Siemens (DPC)		37,8	5,6	15	5	0									5		
(58) Beckman Coulter (Olympus)		38,1	6,0	16	8	0									8		
(60) Roche		37,9	2,4	6,5	28	0									28		
(179) Siemens (Bayer)		36,6	2,2	6,1	11	0									11		
Other					5	0									5		

Sample B1		74,9	4,6	6,2	88			0	CRV	75,6	0,75	24%	57,4	93,8	88	87	99%
(1) Abbott		73,0	5,5	7,6	26	0									26		
(12) Beckman Coulter		74,6	3,4	4,6	5	0									5		
(29) Siemens (DPC)		81,1	9,0	11	5	0									5		
(58) Beckman Coulter (Olympus)		73,8	2,7	3,7	8	0									8		
(60) Roche		75,7	3,4	4,5	28	0									28		
(179) Siemens (Bayer)		77,7	5,7	7,4	11	0									11		
Other					5	0									5		

1x 0, 3x 149, 2x 166, 2x 177																	
1x 0, 1x 149, 2x 166, 1x 177																	
1x 0, 1x 149, 2x 166, 1x 177																	

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM2/18 - Therapeutic Drugs

Dead line: 12.10.2018

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(83) Primidone					9							9	8	89%									0
Samples and groups	[µmol/L]																						
Sample A1		51,1	5,5	11	9		CVP	51,1	6,8	24%	38,8	63,4		9	8	89%							0
(999) another manufacturer		45,5	3,5	7,8	5	0								5									
Other					4	0								4									
							1x 60, 3x 118																
Sample B1		85,1	5,6	6,5	9		CVP	85,1	6,9	24%	64,6	106		9	9	100%							0
(999) another manufacturer		77,9	10	13	5	0								5									
Other					4	0								4									
							1x 60, 3x 118																
(84) Phenobarbital					27									27	26	96%							0
Samples and groups	[µmol/L]																						
Sample A1		47,8	4,0	8,3	27		CVP	47,8	1,9	20%	38,2	57,4		27	26	96%							0
(1) Abbott		50,2	2,2	4,4	9	0								9									
(60) Roche		47,0	1,3	2,7	9	0								9									
Other					9	0								9									
							1x 0, 2x 58, 2x 118, 2x 179, 2x 999																
Sample B1		128	8,4	6,6	27		CVP	128	4,0	20%	102	154		27	27	100%							0
(1) Abbott		133	7,4	5,6	9	0								9									
(60) Roche		122	3,9	3,1	9	0								9									
Other					9	0								9									
							1x 0, 2x 58, 2x 118, 2x 179, 2x 999																
(85) Phenytoin					47									47	42	89%							0
Samples and groups	[µmol/L]																						
Sample A1		75,8	4,9	6,5	47		CVP	75,8	1,8	20%	60,6	91		47	46	98%							0
(1) Abbott		75,6	4,3	5,6	16	0								16									
(60) Roche		75,8	4,6	6,1	15	0								15									
Other					16	0								16									
							1x 12, 3x 29, 3x 58, 2x 118, 1x 149, 3x 179, 3x 999																
Sample B1		12,2	1,2	9,6	47		CVP	12,2	0,42	20%	9,76	14,7		47	43	91%							0
(1) Abbott		12,2	0,68	5,6	16	0								16									
(60) Roche		12,1	0,97	8,0	15	0								15									
Other					16	0								16									
							1x 12, 3x 29, 3x 58, 2x 118, 1x 149, 3x 179, 3x 999																
(86) Carbamazepin					63									63	61	97%							0
Samples and groups	[µmol/L]																						
Sample A1		33,9	2,2	6,5	63		CVP	33,9	0,68	20%	27,1	40,7		63	63	100%							0
(1) Abbott		33,4	2,4	7,0	20	0								20									
(29) Siemens (DPC)		32,5	1,4	4,3	6	0								6									
(60) Roche		33,9	1,6	4,6	19	0								19									
(179) Siemens (Bayer)		37,0	2,9	7,9	5	0								5									
Other					13	0								13									
							1x 0, 2x 12, 4x 58, 2x 118, 1x 149, 3x 999																
Sample B1		31,6	2,3	7,4	63		CVP	31,6	0,72	20%	25,2	38		63	61	97%							0
(1) Abbott		31,0	2,7	8,7	20	0								20									
(29) Siemens (DPC)		30,0	1,9	6,4	6	0								6									
(60) Roche		31,6	1,3	4,1	19	0								19									
(179) Siemens (Bayer)		33,5	1,9	5,6	5	0								5									

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM2/18 - Therapeutic Drugs

Dead line: 12.10.2018

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(86) Carbamazepin	[µmol/L]				63							63	61	97%									0
Samples and groups																							
Sample B1		31,6	2,3	7,4	63		CVP	31,6	0,72	20%	25,2	38	63	61	97%								0
Other					13	0							13										
								1x 0, 2x 12, 4x 58, 2x 118, 1x 149, 3x 999															
(87) Ethosuximide	[µmol/L]				9								9	8	89%								0
Samples and groups																							
Sample A1		572	51	8,8	9		CVP	572	62	24%	434	710	9	8	89%								0
(999) another manufacturer		547	16	3,0	5	0							5										
Other					4	0							4										
								3x 118, 1x 179															
Sample B1		599	62	10	9		CVP	599	76	24%	455	743	9	8	89%								0
(999) another manufacturer		584	71	12	5	0							5										
Other					4	0							4										
								3x 118, 1x 179															
(88) Valproic acid	[µmol/L]				80								80	79	99%								0
Samples and groups																							
Sample A1		249	19	7,6	80		CVP	249	5,2	20%	199	299	80	80	100%								0
(1) Abbott		234	11	4,9	26	0							26										
(29) Siemens (DPC)		252	18	7,1	8	0							8										
(58) Beckman Coulter (Olympus)		282	16	5,8	7	0							7										
(60) Roche		251	12	4,9	27	0							27										
(179) Siemens (Bayer)		268	27	10	8	0							8										
Other					4	0							4										
								1x 0, 2x 12, 1x 149															
Sample B1		388	26	6,7	80		CVP	388	7,1	20%	310	466	80	79	99%								0
(1) Abbott		365	22	5,9	26	0							26										
(29) Siemens (DPC)		386	17	4,4	8	0							8										
(58) Beckman Coulter (Olympus)		439	18	4,1	7	0							7										
(60) Roche		390	15	3,8	27	0							27										
(179) Siemens (Bayer)		404	22	5,5	8	0							8										
Other					4	0							4										
								1x 0, 2x 12, 1x 149															
Set of samples 2																							
(89) Amicacin	[µmol/L]				30								30	28	93%								0
Samples and groups																							
Sample A2		10,3	0,89	8,6	30		CVP	10,3	0,40	20%	8,24	12,4	30	29	97%								0
(60) Roche		10,3	0,79	7,7	18	0							18										
Other					12	0							12										
								1x 0, 4x 1, 3x 12, 2x 58, 1x 149, 1x 166															
Sample B2		29,6	1,2	4,2	30		CVP	29,6	0,55	20%	23,6	35,6	30	29	97%								0
(60) Roche		29,3	0,95	3,2	18	0							18										
Other					12	0							12										
								1x 0, 4x 1, 3x 12, 2x 58, 1x 149, 1x 166															
(90) Gentamicin	[µmol/L]				55								55	47	85%								0
Samples and groups																							
Sample A2		21,7	4,1	19	55		CVP	21,7	1,4	31%	14,9	28,5	55	49	89%								0

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM2/18 - Therapeutic Drugs

Dead line: 12.10.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(90) Gentamicin					55							55	47	85%									0
Samples and groups	[µmol/L]																						
Sample A2		21,7	4,1	19	55	CVP	21,7	1,4	31%	14,9	28,5	55	49	89%									0
(1) Abbott		22,7	2,0	8,8	20							20											
(60) Roche		18,8	5,2	28	21							21											
(179) Siemens (Bayer)		25,0	1,5	5,9	7							7											
Other					7							7											
							1x 0, 3x 12, 3x 58																
Sample B2		17,5	3,0	17	55	CVP	17,5	1,0	31%	12	23	55	49	89%									0
(1) Abbott		19,0	1,1	6,0	20							20											
(60) Roche		14,7	3,3	22	21							21											
(179) Siemens (Bayer)		20,3	2,6	13	7							7											
Other					7							7											
							1x 0, 3x 12, 3x 58																
(92) Vankomycin					58							58	56	97%									0
Samples and groups	[µmol/L]																						
Sample A2		21,1	2,9	14	58	CVP	21,1	0,95	28%	15,1	27,1	58	56	97%									0
(1) Abbott		20,9	1,3	6,0	22							22											
(60) Roche		23,0	3,1	13	23							23											
(179) Siemens (Bayer)		17,1	0,88	5,2	7							7											
Other					6							6											
							1x 0, 2x 12, 2x 58, 1x 149																
Sample B2		9,38	1,0	11	58	CVP	9,38	0,32	28%	6,75	12,1	58	56	97%									0
(1) Abbott		9,29	0,49	5,3	22							22											
(60) Roche		10,1	0,91	9,0	23							23											
(179) Siemens (Bayer)		7,83	0,78	9,9	7							7											
Other					6							6											
							1x 0, 2x 12, 2x 58, 1x 149																
(93) Methotrexate					12							12	11	92%									0
Samples and groups	[µmol/L]																						
Sample A2		4,86	0,55	11	12	CVP	4,86	0,39	30%	3,4	6,32	12	11	92%									0
(1) Abbott		4,71	0,67	14	8							8											
Other					4							4											
							2x 60, 1x 166, 1x 179																
Sample B2		3,11	0,42	14	12	CVP	3,11	0,30	30%	2,17	4,05	12	11	92%									0
(1) Abbott		3,12	0,33	10	8							8											
Other					4							4											
							2x 60, 1x 166, 1x 179																

st_kn_np

End of report

Printed: 19.10.2018